Also people have sometimes been quick to denigrate the value of Acromegaly- but actually the main competitor Acromegaly drug is worth $1 billy annually, and MS main competitor is $1.6 billy annually.
So I really don't think Acromegaly is anything to be shunned in terms of market potential. Anyone looking for more sexy should be doing a different web search I think.
Keeping in mind I suspect we have a better product in the pipeline (based on available data) for both MS and Acromegaly than anything else available in terms of dosage efficacy and cost- together, this is an outrageously strong market potential. Still have Asthma, bone marrow an cancer to go!
ANP Price at posting:
16.0¢ Sentiment: LT Buy Disclosure: Held
